Celon Pharma S.A.

Warsaw Stock Exchange CLN.WA

Celon Pharma S.A. Current Liabilities for the year ending December 31, 2023: USD 21.89 M

Celon Pharma S.A. Current Liabilities is USD 21.89 M for the year ending December 31, 2023, a -17.62% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Celon Pharma S.A. Current Liabilities for the year ending December 31, 2022 was USD 26.58 M, a 24.39% change year over year.
Celon Pharma S.A. Current Liabilities for the year ending December 31, 2021 was USD 21.36 M, a 13.08% change year over year.
Celon Pharma S.A. Current Liabilities for the year ending December 31, 2020 was USD 18.89 M, a 176.34% change year over year.
Celon Pharma S.A. Current Liabilities for the year ending December 31, 2019 was USD 6.84 M, a 29.90% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Warsaw Stock Exchange: CLN.WA

Celon Pharma S.A.

CEO	Dr. Maciej Wieczorek Ph.D.
IPO Date	Feb. 17, 2017
Location	Poland
Headquarters	ul. Ogrodowa
Employees	566
Sector	Healthcare
Industries Pharmaceuticals Biotechnology

Description

Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.

Key trends

Past 5 years